Achilles Therapeutics (ACHL)
NASDAQ: ACHL
· Real-Time Price · USD
1.48
0.00 (0.00%)
At close: Mar 20, 2025, 3:59 PM
Achilles Therapeutics Income Statement
Financials in USD. Fiscal
year is
January - December.
| Fiscal Year | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
| Period Ending | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
Revenue | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 580K | 580K |
Cost of Revenue | 3.52M | 4.71M | 4.84M | 3.66M | 3.34M | 3.03M | 2.62M | 3.67M | 3.67M | 3.67M | 3.58M | 2.53M | 1.69M | 1.09M | 290K |
Gross Profit | -3.52M | -4.71M | -4.84M | -3.66M | -3.34M | -3.03M | -2.62M | -3.67M | -3.67M | -3.67M | -3.58M | -2.53M | -1.69M | -508.44K | 290K |
Operating Income | -72.19M | -70.87M | -71.16M | -75.42M | -78.58M | -75.51M | -77.97M | -78.38M | -74.01M | -73.71M | -69.46M | -64.19M | -58.65M | -51.22M | -41.87M |
Interest Income | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Pretax Income | -66.54M | -63.65M | -64.16M | -69.33M | -75.06M | -70.79M | -71.19M | -71.06M | -65.28M | -65.78M | -64.65M | -61.06M | -55.74M | -51.02M | -41.73M |
Net Income | -67.03M | -64.12M | -64.59M | -69.83M | -75.09M | -70.88M | -71.33M | -71.18M | -65.35M | -65.82M | -64.69M | -61.1M | -55.79M | -51.05M | -41.75M |
Selling & General & Admin | 13.66M | 14.02M | 14.17M | 15.88M | 17.34M | 18.4M | 19.85M | 21.12M | 23.82M | 23.42M | 23.09M | 21.97M | 19.28M | 17.24M | 14.19M |
Research & Development | 56.2M | 54.51M | 54.65M | 58.38M | 61.23M | 57.12M | 58.12M | 57.26M | 50.19M | 50.29M | 46.36M | 42.22M | 39.38M | 33.97M | 27.68M |
Other Expenses | n/a | 2.39M | 3.6M | 3.6M | 2.42M | 3.63M | 5.69M | 7.32M | 8.72M | 7.93M | 4.81M | 3.13M | 2.91M | 193K | 47K |
Operating Expenses | 69.85M | 68.53M | 68.83M | 74.27M | 78.58M | 75.51M | 77.97M | 78.38M | 74.01M | 73.71M | 69.46M | 64.19M | 58.65M | 51.22M | 41.87M |
Interest Expense | n/a | n/a | n/a | n/a | 1.18M | 1.18M | 1.18M | 1.18M | n/a | n/a | n/a | 45K | 45K | 45K | 45K |
Selling & Marketing Expenses | -2.31M | -2.31M | -2.31M | -1.13M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 72.19M | 70.87M | 71.16M | 75.42M | 78.58M | 75.51M | 77.97M | 78.38M | 74.01M | 73.71M | 69.46M | 64.19M | 58.65M | 51.22M | 41.87M |
Income Tax Expense | 489.41K | 470.41K | 428.41K | 495.39K | 27K | 92K | 140K | 111K | 66K | 41K | 40K | 37K | 44K | 28.75K | 16.5K |
Shares Outstanding (Basic) | 40.43M | 40.36M | 40.28M | 40.19M | 40.07M | 39.9M | 39.73M | 39.52M | 39.31M | 39.1M | 38.89M | 28.65M | 38.26M | 35.68M | 38.15M |
Shares Outstanding (Diluted) | 40.43M | 40.36M | 40.28M | 40.19M | 40.07M | 39.9M | 39.73M | 39.52M | 39.31M | 39.1M | 38.89M | 28.65M | 38.26M | 35.68M | 38.15M |
EPS (Basic) | -1.66 | -1.6 | -1.61 | -1.75 | -1.89 | -1.79 | -1.81 | -1.82 | -1.85 | -1.87 | -1.88 | -1.79 | -1.47 | -6.13 | -9.85 |
EPS (Diluted) | -1.66 | -1.6 | -1.61 | -1.75 | -1.89 | -1.79 | -1.81 | -1.82 | -1.85 | -1.87 | -1.88 | -1.79 | -1.47 | -6.13 | -9.85 |
EBITDA | -68.42M | -65.9M | -66.12M | -70.44M | -75.53M | -72.79M | -75.58M | -76.05M | -70.54M | -70.3M | -66.13M | -61.14M | -55.8M | -49.03M | -40.41M |
EBIT | -72.03M | -70.71M | -71M | -75.25M | -79.94M | -76.87M | -79.33M | -79.74M | -74.01M | -73.71M | -69.46M | -64.19M | -58.65M | -51.22M | -41.87M |
Depreciation & Amortization | 3.52M | 4.71M | 4.84M | 4.77M | 4.45M | 4.14M | 3.73M | 3.67M | 3.67M | 3.67M | 3.58M | 3.32M | 2.88M | 2.16M | 1.46M |